Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

Vertex (market cap $117.7B) and Medtronic (market cap $129B) are positioned for stronger 2026 performance as Vertex benefits from its cystic fibrosis franchise, the newly approved oral non-opioid pain drug Journavx, planned FDA submission for zimislecel in type 1 diabetes and late-stage programs (inaxaplin, povetacicept); Medtronic is riding momentum from Pulse Field Ablation product launches and received clearance for the Hugo robotic-assisted surgery system while planning a diabetes-care spin-off that historically represented 8% of revenue and 4% of operating profit in FY2025. By contrast Pfizer (market cap $144B) faces near-term headwinds from guidance weakness, imminent patent cliffs including Eliquis and a lack of near-term trial readouts to replace COVID-19 revenues, making it plausible investors could favor Vertex or Medtronic in 2026. Investors should weigh pipeline catalysts, regulatory milestones and the valuation implications of Medtronic's planned separation when positioning relative to Pfizer risk from patent expiries.

Analysis

Market structure: Winners are VRTX and MDT — Vertex's CF franchise is highly price-inelastic (durable EBITDA margins) and Journavx offers upside into a large non-opioid pain TAM; Medtronic benefits from recurring device install base and incremental margin expansion after the diabetes spinoff. Loser is PFE, facing near-term revenue erosion from Eliquis and COVID cliffs (market caps: VRTX $117.7B, MDT $129B, PFE $144B), implying possible re-ranking if 2026 growth gaps persist. Cross-asset: a healthcare/biotech bid would be risk-on — expect modest Treasury selloff (-5–15bp) and tighter credit spreads for high-grade hospital/medtech names; equity vols should compress for successful readouts and spike around FDA decisions.

Risk assessment: Tail risks include pivotal clinical failures for zimislecel or inaxaplin (30–40% downside on readout failure), FDA non-approval for Journavx market expansion, and Medicare reimbursement cuts for high-priced specialty drugs. Time horizons: immediate (days-weeks) volatility around earnings and regulatory updates, short-term (3–9 months) binary FDA filings and Hugo indication tests, long-term (1–3 years) structural shifts from Medtronic’s spinoff and potential Pfizer M&A. Hidden deps: Vertex revenue concentrated in CF; pricing/payer pushback is a second-order risk; Medtronic’s Hugo adoption depends on hospital capex cycles.

Key Decisions for Investors

• Establish a 2–3% long position in VRTX over next 6–12 months, accumulating into dips of 10–15%; hedge with a small notional (0.5%) long put (3–6 month, ~10% OTM) around major FDA submission windows (expect submissions/readouts within 3–9 months).
• Initiate a 1.5–2% long position in MDT and buy a 6–12 month call spread (bull call spread funded by selling a higher strike) to express Hugo adoption upside while capping premium; target exit on a 20–30% relative outperformance or after FY2026 guidance update.
• Implement a pair trade: equal-dollar long VRTX / short PFE (1–2% each) to capture asymmetric upside from Vertex pipeline vs Pfizer patent cliffs; cover/trim short if Pfizer announces a material M&A (> $5B) or better-than-expected 2026 guidance.
• Tactical options: buy 9–12 month VRTX LEAPS (delta ~0.30) sized to 50% of the cash long and sell 6–9 month out-of-the-money PFE call spreads to finance premium; alternatively buy 3-month PFE 5–8% OTM puts ahead of key catalyst windows (Eliquis patent rulings or earnings).
• Reduce broad big-pharma exposure by ~2–3% and redeploy into specialty biotech/medtech for 6–12 months; reassess after key FDA readouts or if VRTX market share gains for Journavx exceed 15% of estimated addressable pain Rx market within 12 months.